Abstract
GEN EdgeVol. 5, No. 1 TopicsFuture Fields and Jenthera Use Fruit Flies for In Vivo CRISPR TherapyBy combining a novel cell-specific, in vivo drug delivery mechanism and bioproduction platform, the two Canadian companies lay the groundwork for a cost-effective, scalable, and sustainable method of mass-producing therapeutic recombinant proteinsJonathan D GrinsteinJonathan D GrinsteinSearch for more papers by this authorPublished Online:14 Jun 2023https://doi.org/10.1089/genedge.5.1.87AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 5Issue 1Jan 2023 Information© 2023 by GEN PublishingTo cite this article:Jonathan D Grinstein.Future Fields and Jenthera Use Fruit Flies for In Vivo CRISPR Therapy.GEN Edge.Jan 2023.443-446.http://doi.org/10.1089/genedge.5.1.87Published in Volume: 5 Issue 1: June 14, 2023PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
